{"slug":"ara-vs-gabapentin-comparison","verification":{"valid":true,"entries":29,"head":"34b25c788e9306dfc84788bb008a0c59511d31f773ff7b557b0ea43f898351bb"},"energy":{"passes":29,"tokens_in":13797,"tokens_out":1937,"tokens_total":15734,"cost_usd":0,"models":{"grok/grok-4.3":2,"grok-4.3":12,"system/audit-repair":9,"kimi/moonshot-v1-8k":1,"gemini/gemini-2.5-flash":1,"repair":1,"fill-slots":2,"owner":1},"head":"34b25c788e9306dfc84788bb008a0c59511d31f773ff7b557b0ea43f898351bb"},"provenance":[{"ts":"2026-06-29T09:07:02.191Z","model":"grok/grok-4.3","action":"write","prompt":"","input":"PEPTIDE DEFINITIONS (use for mechanism accuracy; no medical claims):\nBPC-157 — Body Protection Compound. Derived from gastric juice protein. Builds new blood vessels into damaged tissue locally. 100+ animal/cell studies (tendon, gut, muscle, bone, nerve).\nTB-500 — Synthetic Thymosin Beta-4. Moves repair cells to damage; clears stuck inflammation systemically. Production drops ~60% by age 60.\nARA-290 — Nerve repair peptide with human clinical trial data. Regrows damaged nerves; does not mask nerve pain.\nSemax — Brain peptide; upregulates BDNF for neuroprotection and cognitive recovery.\nSelank — Anxiolytic peptide; reduces anxiety without sedation or addiction (non-benzodiazepine pathway).\nPT-141 — Sexual function; brain-level arousal signaling (FDA-approved mechanism as Vyleesi).\nDSIP — Delta Sleep Inducing Peptide; natural deep sleep without Ambien-class hangover.\nKPV — Gut-specific anti-inflammatory; calms gut lining without systemic immune suppression.\nGHK-Cu — Tissue remodeling; builds collagen scaffolding. Production drops 60-80% with age.\nThymosin Alpha-1 — Immune modulation; supports immune function without suppressing it.\n\nWrite a data-first, evidence-graded article: ARA-290 vs Gabapentin: Nerve Repair vs Symptom Masking\n\nAudience: 15M. Content: gabapentin dampens nerve signals and masks pain. ARA-290 regrows the nerve. One silences the alarm; the other fixes what set it off. Novelty: 9/10.\n\nRules: label every claim tier (human|preclinical|anecdotal|mechanistic|speculative). Separate rat studies from human trials from user reports. No medical claims or treatment promises. Use repair-vs-suppression framing where relevant. register: source_ledger.","response":"{\n  \"slug\": \"ara-290-vs-gabapentin-nerve-repair-vs-symptom-masking\",\n  \"title\": \"ARA-290 vs Gabapentin: Nerve Repair vs Symptom Masking\",\n  \"body\": \"## Overview\\n\\nARA-290 is described as activating the innate repair receptor to promote tissue repair and nerve fiber regrowth. Gabapentin reduces excitatory neurotransmitter release via calcium channel modulation.\\n\\n## ARA-290 Evidence\\n\\nHuman trials in sarcoidosis-associated small fiber neuropathy reported improvements in neuropathic symptom scores and corneal nerve fiber density increases after 28 days (human). Similar symptom improvements and metabolic effects noted in type 2 diabetes patients (human). Preclinical models showed reduced inflammation and nerve morphology improvements (preclinical).\\n\\n## Gabapentin Evidence\\n\\nGabapentin binds α2δ subunits of voltage-gated calcium channels, inhibiting presynaptic release of excitatory neurotransmitters and thereby dampening pain signal transmission (human). It does not restore damaged nerve structure or function (mechanistic). Established use in neuropathic pain management relies on symptom reduction without disease modification (human).\\n\\n## Comparative Framing\\n\\nARA-290 studies indicate potential for nerve fiber regrowth alongside symptom changes in specific populations (human). Gabapentin primarily suppresses signal propagation (mechanistic). No head-to-head trials identified. Human data for ARA-290 limited to small trials in sarcoidosis and diabetes; no broad approval status reported.\\n\\n## Data Limitations\\n\\nWhere no human data exists for direct comparisons or long-term outcomes, this is stated plainly. All claims graded by evidence tier below.\",\n  \"register\": \"source_ledger\",\n  \"claims\": [\n    {\n      \"id\": \"c1\",\n      \"text\": \"ARA-290 treatment for 28 days initiated regrowth of small nerve fibers in the cornea in sarcoidosis patients.\",\n      \"section\": \"ARA-290 Evidence\",\n      \"tier\": \"human\",\n      \"source_ids\": [\"s1\"],\n      \"source_status\": \"sourced\",","tokens_in":0,"tokens_out":0,"cost":0,"prev":"genesis","hash":"8e599e8a47f09c682be6aba39da27499dd4646fcc11a4dffa34b08219937a6e6"},{"ts":"2026-06-29T11:38:11.361Z","model":"grok-4.3","action":"sources","prompt":"","input":"ara-vs-gabapentin-comparison","response":"4 source(s) added","tokens_in":0,"tokens_out":0,"cost":0,"prev":"8e599e8a47f09c682be6aba39da27499dd4646fcc11a4dffa34b08219937a6e6","hash":"516ac549b55c51328f248a402c40bde37dab9610f3815d08ef414dd3bdf00cda"},{"ts":"2026-06-29T11:38:38.451Z","model":"grok-4.3","action":"sources","prompt":"","input":"ara-vs-gabapentin-comparison","response":"8 source(s) added","tokens_in":0,"tokens_out":0,"cost":0,"prev":"516ac549b55c51328f248a402c40bde37dab9610f3815d08ef414dd3bdf00cda","hash":"a5a0aa56470d3f97352c1b58dfebeb664e1b41ade56f436abc391bfbc3dcd8ee"},{"ts":"2026-06-29T11:39:09.182Z","model":"grok-4.3","action":"sources","prompt":"","input":"ara-vs-gabapentin-comparison","response":"2 source(s) added","tokens_in":0,"tokens_out":0,"cost":0,"prev":"a5a0aa56470d3f97352c1b58dfebeb664e1b41ade56f436abc391bfbc3dcd8ee","hash":"a6ffcf8039e222c61ec01c7c960c785abf7e11190aa2485778e60d5b13cdc8a9"},{"ts":"2026-06-29T11:40:12.946Z","model":"grok-4.3","action":"sources","prompt":"","input":"ara-vs-gabapentin-comparison","response":"7 source(s) added","tokens_in":0,"tokens_out":0,"cost":0,"prev":"a6ffcf8039e222c61ec01c7c960c785abf7e11190aa2485778e60d5b13cdc8a9","hash":"4cfda76e2f1e3c4cd022c2e9ad5d39fd10a01532e4c9112cc10d50613187f1ce"},{"ts":"2026-06-29T11:40:41.449Z","model":"grok-4.3","action":"sources","prompt":"","input":"ara-vs-gabapentin-comparison","response":"6 source(s) added","tokens_in":0,"tokens_out":0,"cost":0,"prev":"4cfda76e2f1e3c4cd022c2e9ad5d39fd10a01532e4c9112cc10d50613187f1ce","hash":"fe69294db28be38224a9c4728a9d91b18e2bcc9d1e01a493fda7eab11177218c"},{"ts":"2026-06-29T11:41:07.050Z","model":"grok-4.3","action":"sources","prompt":"","input":"ara-vs-gabapentin-comparison","response":"5 source(s) added","tokens_in":0,"tokens_out":0,"cost":0,"prev":"fe69294db28be38224a9c4728a9d91b18e2bcc9d1e01a493fda7eab11177218c","hash":"ba081b9e49d18c6d498bd403a192495e80738929b53a2ae5b1dd9b8c5d036497"},{"ts":"2026-06-29T11:41:35.265Z","model":"grok-4.3","action":"sources","prompt":"","input":"ara-vs-gabapentin-comparison","response":"4 source(s) added","tokens_in":0,"tokens_out":0,"cost":0,"prev":"ba081b9e49d18c6d498bd403a192495e80738929b53a2ae5b1dd9b8c5d036497","hash":"c8c317fe284a396965ce4da00ab9ab65d7385882a95816da6e4d87e298bc6b80"},{"ts":"2026-06-29T11:42:16.863Z","model":"grok-4.3","action":"sources","prompt":"","input":"ara-vs-gabapentin-comparison","response":"6 source(s) added","tokens_in":0,"tokens_out":0,"cost":0,"prev":"c8c317fe284a396965ce4da00ab9ab65d7385882a95816da6e4d87e298bc6b80","hash":"2ab7d302399a766a8f7ae2d72e620439b5db3abe8ec52cfe3efa4a6ddf597006"},{"ts":"2026-06-29T11:42:47.847Z","model":"grok-4.3","action":"sources","prompt":"","input":"ara-vs-gabapentin-comparison","response":"5 source(s) added","tokens_in":0,"tokens_out":0,"cost":0,"prev":"2ab7d302399a766a8f7ae2d72e620439b5db3abe8ec52cfe3efa4a6ddf597006","hash":"c572da1b9536400255ca4d25c07241f89138249123a0c70fe4ac77b305b0fc6c"},{"ts":"2026-06-29T12:49:37.657Z","model":"system/audit-repair","action":"repair","prompt":"","input":"ara-vs-gabapentin-comparison","response":"{\"materialized\":0,\"before\":[\"missing constitution slots: what_it_is, what_is_known, what_is_unknown, limitations, disclaimer\"],\"after\":[\"missing constitution slots: what_it_is, what_is_known, what_is_unknown, limitations, disclaimer\"]}","tokens_in":0,"tokens_out":0,"cost":0,"prev":"c572da1b9536400255ca4d25c07241f89138249123a0c70fe4ac77b305b0fc6c","hash":"ba05b83ba433832aa29b1d3c4d3157fe9c1a40ff3e0cd73fc787a2169489018c"},{"ts":"2026-06-29T12:49:38.292Z","model":"system/audit-repair","action":"claim","prompt":"","input":"ara-vs-gabapentin-comparison c51","response":"ARA-290 vs Gabapentin: Nerve Repair vs Symptom Masking is catalogued in this miscsubjects ledger as a tier-honest evidence graph (claims + hash-chained sources). This page summarizes what is claimed in the literature and online about the topic — not clinical recommendations.","tokens_in":0,"tokens_out":0,"cost":0,"prev":"ba05b83ba433832aa29b1d3c4d3157fe9c1a40ff3e0cd73fc787a2169489018c","hash":"ecbf8066631a8203f217b848214df64d93e98c51346ecf7a18de5583dbe809bc"},{"ts":"2026-06-29T12:49:38.461Z","model":"system/audit-repair","action":"claim","prompt":"","input":"ara-vs-gabapentin-comparison c52","response":"Per this ledger on ARA-290 vs Gabapentin: Nerve Repair vs Symptom Masking: 25 scientific and 21 anecdotal sources are catalogued; 11 preclinical claim(s) summarize animal/cell literature in-catalogue.","tokens_in":0,"tokens_out":0,"cost":0,"prev":"ecbf8066631a8203f217b848214df64d93e98c51346ecf7a18de5583dbe809bc","hash":"d96663fdbba6b4d7d7db0476adfbc2da252dd15a108d3d76c0998fcbb61ddffc"},{"ts":"2026-06-29T12:49:38.523Z","model":"system/audit-repair","action":"claim","prompt":"","input":"ara-vs-gabapentin-comparison c53","response":"Not established in this ledger: large randomized human trials for common marketed uses; long-term human safety beyond small pilots; condition-specific efficacy where only anecdotal or preclinical sources exist (explicit gaps remain in question graph).","tokens_in":0,"tokens_out":0,"cost":0,"prev":"d96663fdbba6b4d7d7db0476adfbc2da252dd15a108d3d76c0998fcbb61ddffc","hash":"267e1f9c5402671df96bf616dac93f14bd474848b9b606be88dfa1a065590abe"},{"ts":"2026-06-29T12:49:38.589Z","model":"system/audit-repair","action":"claim","prompt":"","input":"ara-vs-gabapentin-comparison c54","response":"Hash-chained sources verify integrity, not clinical truth. Evidence mix is predominantly preclinical and anecdotal; human data are sparse. No dosing, protocol, or treatment recommendations — catalogue only.","tokens_in":0,"tokens_out":0,"cost":0,"prev":"267e1f9c5402671df96bf616dac93f14bd474848b9b606be88dfa1a065590abe","hash":"d3ae1815939ead91f4dff181c1776640ea8530a97e273aacb93ddc3b2129cc54"},{"ts":"2026-06-29T12:49:38.840Z","model":"system/audit-repair","action":"claim","prompt":"","input":"ara-vs-gabapentin-comparison c55","response":"Not medical advice. Tier-honest research catalogue only — consult qualified healthcare professionals for personal health decisions.","tokens_in":0,"tokens_out":0,"cost":0,"prev":"d3ae1815939ead91f4dff181c1776640ea8530a97e273aacb93ddc3b2129cc54","hash":"3bcb2b1c3d04c67d9652019134cc798388df21a04615d639ccc90bc5a0afdaed"},{"ts":"2026-06-29T12:49:39.682Z","model":"system/audit-repair","action":"repair","prompt":"","input":"ara-vs-gabapentin-comparison","response":"{\"materialized\":0,\"before\":[],\"after\":[]}","tokens_in":0,"tokens_out":0,"cost":0,"prev":"3bcb2b1c3d04c67d9652019134cc798388df21a04615d639ccc90bc5a0afdaed","hash":"bf4e8147480a7d55bf42369941463a63c6a9a272674c61b930a5770fbd302d5a"},{"ts":"2026-06-29T13:22:49.578Z","model":"system/audit-repair","action":"repair","prompt":"","input":"ara-vs-gabapentin-comparison","response":"{\"materialized\":0,\"before\":[],\"after\":[]}","tokens_in":0,"tokens_out":0,"cost":0,"prev":"bf4e8147480a7d55bf42369941463a63c6a9a272674c61b930a5770fbd302d5a","hash":"7dfc226313ecd123d53e691c98b5b0783a11f5fb642d0c3083e5b686b31922bc"},{"ts":"2026-06-29T13:22:50.886Z","model":"system/audit-repair","action":"repair","prompt":"","input":"ara-vs-gabapentin-comparison","response":"{\"materialized\":0,\"before\":[],\"after\":[]}","tokens_in":0,"tokens_out":0,"cost":0,"prev":"7dfc226313ecd123d53e691c98b5b0783a11f5fb642d0c3083e5b686b31922bc","hash":"ad24d018127018973a5b240158639119bf01782ff22c2b151c745bf4013a78c5"},{"ts":"2026-06-29T13:26:38.176Z","model":"kimi/moonshot-v1-8k","action":"collaborate","prompt":"","input":"ara-vs-gabapentin-comparison","response":"As Kimi, I am adding explicit gaps in knowledge (what_is_unknown) and identifying who claims what from anecdotes where this information is missing, as per the instructions.","tokens_in":3147,"tokens_out":309,"cost":0,"prev":"ad24d018127018973a5b240158639119bf01782ff22c2b151c745bf4013a78c5","hash":"6c6094b4790aa0c78d226b63c44bc114b2e573f58357df5e2e7304fc02181d43"},{"ts":"2026-06-29T14:55:51.045Z","model":"gemini/gemini-2.5-flash","action":"collaborate","prompt":"","input":"ara-vs-gabapentin-comparison","response":"As Gemini, I've added three tier-honest claims to fill gaps in the ledger, focusing on 'who_claims_what' from existing but unused sources. I also challenged a claim where the tiering appeared inconsistent with the described evidence, ensuring the ledger's accuracy. I am not Grok.","tokens_in":2831,"tokens_out":515,"cost":0,"prev":"6c6094b4790aa0c78d226b63c44bc114b2e573f58357df5e2e7304fc02181d43","hash":"2dc382f24993221610c11aeaf0b7cebc8d8a4a0da8938f9426e32fc77ec7da9f"},{"ts":"2026-06-29T14:56:49.578Z","model":"grok/grok-4.3","action":"synthesize_body","prompt":"","input":"ara-vs-gabapentin-comparison","response":"## Regeneration vs degeneration — where this fits\n\nThe body breaks tissue down and builds it back at the same time. When breakdown exceeds repair, small fiber nerves lose density and function. Gabapentin reduces pain signal transmission without changing nerve structure. ARA-290 is studied for activation of the innate repair receptor, which may shift the balance toward nerve regrowth and reduced inflammation.\n\n## What it is\n\nARA-290 is an 11-amino-acid peptide derived from erythropoietin that does not raise red blood cell count. Gabapentin is a prescription drug that binds the alpha-2-delta subunit of voltage-gated calcium channels.\n\n## How it works\n\nARA-290 binds the innate repair receptor formed by the EPO receptor and the beta-common receptor. Binding reduces NLRP3 inflammasome activity, lowers inflammatory cytokines, and supports small nerve fiber regrowth in some tissues. Gabapentin blocks presynaptic calcium influx, reduces glutamate release, and activates astrocytic glutamate uptake. These actions dampen pain signaling but do not restore nerve fibers.\n\n## Why it would work (logic chain)\n\nIf nerve loss drives neuropathic pain, restoring fiber density should reduce symptoms at the source. If inflammation maintains the degenerative state, lowering cytokine levels should slow further loss. If gabapentin only changes signal strength, pain returns when the drug leaves the system. If ARA-290 changes tissue structure, measured improvements in corneal nerve fiber density or skin biopsy should persist after the compound clears.\n\n## Why people take it\n\nPeople take gabapentin to lower daily pain scores and improve sleep. People take ARA-290 in the hope of measurable nerve repair in addition to pain reduction. Some users report attempting to lower gabapentin dose after trying ARA-290.\n\n## How many people take it\n\nNo public registry tracks either compound for neuropathy. Gabapentin prescriptions number in the tens of millions annually in the United States. ARA-290 use outsi","tokens_in":7819,"tokens_out":1113,"cost":0,"prev":"2dc382f24993221610c11aeaf0b7cebc8d8a4a0da8938f9426e32fc77ec7da9f","hash":"a11adbfde30778d944784153d6556ba4a876fbd281dea0ee4bfda26bee4209f1"},{"ts":"2026-06-29T15:00:27.128Z","model":"grok-4.3","action":"sources","prompt":"","input":"ara-vs-gabapentin-comparison","response":"1 source(s) added","tokens_in":0,"tokens_out":0,"cost":0,"prev":"a11adbfde30778d944784153d6556ba4a876fbd281dea0ee4bfda26bee4209f1","hash":"c7a8c59efed30ab47b9d216dad264df5d0758248838c9a6d4bd8ce099854c023"},{"ts":"2026-06-29T18:51:36.623Z","model":"grok-4.3","action":"sources","prompt":"","input":"ara-vs-gabapentin-comparison","response":"6 source(s) added","tokens_in":0,"tokens_out":0,"cost":0,"prev":"c7a8c59efed30ab47b9d216dad264df5d0758248838c9a6d4bd8ce099854c023","hash":"68dac929b21bb7d5d441a3ff881330689d238710095fe73228035fccfd1997a3"},{"ts":"2026-06-29T18:52:07.685Z","model":"grok-4.3","action":"sources","prompt":"","input":"ara-vs-gabapentin-comparison","response":"7 source(s) added","tokens_in":0,"tokens_out":0,"cost":0,"prev":"68dac929b21bb7d5d441a3ff881330689d238710095fe73228035fccfd1997a3","hash":"0ed0b969bc62f9a55ed1dceb3a2da44edc02fd1b3a4ca104d47ed2904551c1bc"},{"ts":"2026-06-29T20:14:03.540Z","model":"repair","action":"repair","prompt":"","input":"ara-vs-gabapentin-comparison","response":"{\"materialized\":0,\"before\":[],\"after\":[],\"focus_stats\":{\"roles_assigned\":0,\"excluded_sources\":0,\"commercial_sources\":0,\"cut_claims\":0,\"core\":0,\"cycle\":0,\"adjacent\":20}}","tokens_in":0,"tokens_out":0,"cost":0,"prev":"0ed0b969bc62f9a55ed1dceb3a2da44edc02fd1b3a4ca104d47ed2904551c1bc","hash":"1306a4f9e421291fb2c17d49001c706193093c13b7b322639e64bd1ad2bd8779"},{"ts":"2026-06-29T21:25:03.818Z","model":"fill-slots","action":"claim","prompt":"","input":"ara-vs-gabapentin-comparison c76","response":"ARA-290 vs Gabapentin: Nerve Repair vs Symptom Masking is catalogued in this miscsubjects ledger as a tier-honest evidence graph (claims + hash-chained sources). This page summarizes what is claimed in the literature and online about the topic — not clinical recommendations.","tokens_in":0,"tokens_out":0,"cost":0,"prev":"1306a4f9e421291fb2c17d49001c706193093c13b7b322639e64bd1ad2bd8779","hash":"9a0c4484a6460203fa2190c0244b7dc4ee5481d8d5b1b4206e40abbde03ba9a7"},{"ts":"2026-06-29T21:25:06.691Z","model":"fill-slots","action":"claim","prompt":"","input":"ara-vs-gabapentin-comparison c77","response":"Hash-chained sources verify integrity, not clinical truth. Evidence mix is predominantly preclinical and anecdotal; human data are sparse. No dosing, protocol, or treatment recommendations — catalogue only.","tokens_in":0,"tokens_out":0,"cost":0,"prev":"9a0c4484a6460203fa2190c0244b7dc4ee5481d8d5b1b4206e40abbde03ba9a7","hash":"adb100838c9cda1438fe5c6ce0b3af95853ca6d0e90d85a0a886c585bf2e04e1"},{"ts":"2026-07-17T02:38:18.413Z","model":"owner","action":"voxel_divide","prompt":"","input":"ara-vs-gabapentin-comparison","response":"24 DIVs from body (verbatim, roundtrip-checked)","tokens_in":0,"tokens_out":0,"cost":0,"prev":"adb100838c9cda1438fe5c6ce0b3af95853ca6d0e90d85a0a886c585bf2e04e1","hash":"34b25c788e9306dfc84788bb008a0c59511d31f773ff7b557b0ea43f898351bb"}]}